Stirling products to test growth promotors in sheep.
Wednesday, 30 June, 2004
Perth-based Stirling Products (ASX:STI) is preparing for the first animal trials of its ST810 growth promotion agent in sheep.
This trial will test the affect of ST810's -- a beta-2 agonist -- on tissue weight gain and carcass quality. In published scientific literature beta-agonists have been reported to increase lean meat in sheep from 15 to 35 per cent and reduce carcass fat from 25 to 45 per cent.
Because it is a pure 'single enantiomer' molecule, rather than a mix of right and left-handed enantiomers, STA-810 stimulates only beta-2 receptors. Current growth promotant products are both beta-1 and beta-2 agonists. Selectively stimulating beta-2 receptors may mean decreased side-effects, as beta-1 agonists are associated with increased heart rate.
The trial is scheduled to commence in early spring following trial protocol and animal ethics submissions.
Shares in Stirling were up 5 per cent to AUD$0.205.
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
